• Users Online: 568
  • Print this page
  • Email this page
Year : 2013  |  Volume : 3  |  Issue : 4  |  Page : 128-133

Vascular endothelial growth factor and its inhibitor in age-related macular degeneration

1 Department of Ophthalmology, Shiga University of Medical Science, Shiga, Japan; Key Laboratory of Harbin Medical University Eye Center, Eye Hospital, First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China
2 Department of Ophthalmology, Shiga University of Medical Science, Shiga, Japan

Correspondence Address:
Masahito Ohji
Department of Ophthalmology, Shiga University of Medical Science, Seta Tukinowacho, Otsu, Shiga 520-2192
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.1016/j.tjo.2013.09.002

Rights and Permissions

Intraocular angiogenesis is considered the leading cause for severe loss of vision, and contributes to many ocular diseases such as neovascular age-related macular degeneration, diabetic retinopathy, and retinopathy of prematurity, the main causes of blindness in developed countries.[1] An enormous body of work has demonstrated that vascular endothelial growth factor (VEGF) plays a prominent role as mediator in the procedure of pathological angiogenesis. This makes VEGF a potential target for the medical therapies of retinal angiogenesis and some clinical trials have proved the efficacy of anti-VEGF strategies. This review evaluates the role of VEGF in the pathogenesis of age-related macular degeneration and provides an overview of recent developments in therapeutic modalities.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded147    
    Comments [Add]    
    Cited by others 3    

Recommend this journal